Effect of hypertonic saline on mucociliary clearance and clinical outcomes in chronic bronchitis
| Autor: | Brian Button, Richard C. Boucher, William D. Bennett, Fred Fuller, Christine Gladman, Agathe Ceppe, Ashley G. Henderson, S. Gazda, Scott H. Donaldson, Kirby L. Zeman, Jihong Wu |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Pulmonary and Respiratory Medicine
Spirometry medicine.medical_specialty Chronic bronchitis Mucociliary clearance medicine.medical_treatment Population lcsh:Medicine 030204 cardiovascular system & hematology Gastroenterology 03 medical and health sciences 0302 clinical medicine Internal medicine medicine COPD education Saline education.field_of_study medicine.diagnostic_test business.industry lcsh:R Original Articles medicine.disease Crossover study Hypertonic saline 030228 respiratory system business |
| Zdroj: | ERJ Open Research article-version (VoR) Version of Record ERJ Open Research, Vol 6, Iss 3 (2020) |
| ISSN: | 2312-0541 |
| DOI: | 10.1183/23120541.00269-2020 |
| Popis: | Background Mucus dehydration and impaired mucus clearance are common features of cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD). In CF, inhaled hypertonic saline (HS) improves lung function and produces sustained increases in mucociliary clearance (MCC). We hypothesised that administration of HS (7% NaCl) twice daily for 2 weeks would improve clinical outcomes and produce sustained increases in MCC in COPD subjects with a chronic bronchitis (CB) phenotype. Methods Twenty-two CB subjects completed a double-blinded, crossover study comparing inhaled HS to a hypotonic control solution (0.12% saline) administered via nebuliser twice daily for 2 weeks. Treatment order was randomised. During each treatment period, symptoms and spirometry were measured. MCC was measured at baseline, shortly after initial study agent administration, and approximately 12 h after the final dose. Results HS was safe and well tolerated but overall produced no significant improvements in spirometry or patient-reported outcomes. CB subjects had slower baseline MCC than healthy subjects. The MCC rates over 60 min (Ave60Clr) in CB subjects following 2 weeks of HS were not different from 0.12% saline but were slower than baseline (Ave60Clr was 9.1±6.3% at baseline versus 5.3±6.9% after HS; p 2-week HS treatment in CB does not lead to overall improvement in baseline mucociliary clearance. However, a subgroup of patients with residual, noncough-induced central airway clearance does show improvement in both spirometry and symptoms. https://bit.ly/36ji6Vn |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|